Panobinostat is primarily approved for use in combination with other therapies for treating multiple myeloma, especially in patients who have received at least two prior standard therapies, including a proteasome inhibitor and an immunomodulatory agent. Research is ongoing to explore its potential in treating other types of cancer, including lymphomas and leukemias, as well as solid tumors.
